Intervention Review

Sargramostim (GM-CSF) for induction of remission in Crohn's disease

  1. Lee Roth2,
  2. John K MacDonald3,
  3. John WD McDonald3,
  4. Nilesh Chande1,*

Editorial Group: Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group

Published Online: 9 NOV 2011

Assessed as up-to-date: 19 APR 2011

DOI: 10.1002/14651858.CD008538.pub2


How to Cite

Roth L, MacDonald JK, McDonald JWD, Chande N. Sargramostim (GM-CSF) for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2011, Issue 11. Art. No.: CD008538. DOI: 10.1002/14651858.CD008538.pub2.

Author Information

  1. 1

    London Health Sciences Centre - Victoria Hospital, London, Ontario, Canada

  2. 2

    McMaster University, Faculty of Health Sciences, Hamilton, ON, Canada

  3. 3

    Robarts Research Institute, Robarts Clinical Trials, London, Ontario, Canada

*Nilesh Chande, London Health Sciences Centre - Victoria Hospital, Room E1-423A, 800 Commissioners Road East, London, Ontario, N6A 5W9, Canada. nchande2@uwo.ca.

Publication History

  1. Publication Status: New
  2. Published Online: 9 NOV 2011

SEARCH

  1. Current Version

    Sargramostim (GM-CSF) for induction of remission in Crohn's disease

    Lee Roth, John K MacDonald, John WD McDonald and Nilesh Chande

    Article first published online: 9 NOV 2011 | DOI: 10.1002/14651858.CD008538.pub2

Previous versions of this article and their online publication dates

  1. Version 1

    Sargramostim (GM-CSF) for induction of remission in Crohn's disease

    Lee Roth, John K MacDonald, John WD McDonald and Nilesh Chande

    Article first published online: 16 JUN 2010 | DOI: 10.1002/14651858.CD008538